JP6263773B2 - 水溶性膜タンパク質およびその調製および使用方法 - Google Patents
水溶性膜タンパク質およびその調製および使用方法 Download PDFInfo
- Publication number
- JP6263773B2 JP6263773B2 JP2013555565A JP2013555565A JP6263773B2 JP 6263773 B2 JP6263773 B2 JP 6263773B2 JP 2013555565 A JP2013555565 A JP 2013555565A JP 2013555565 A JP2013555565 A JP 2013555565A JP 6263773 B2 JP6263773 B2 JP 6263773B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- gpcr
- variant
- receptors
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims 5
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 14
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 102000002020 Protease-activated receptors Human genes 0.000 claims 2
- 108050009310 Protease-activated receptors Proteins 0.000 claims 2
- 102000000033 Purinergic Receptors Human genes 0.000 claims 2
- 108010080192 Purinergic Receptors Proteins 0.000 claims 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 230000005660 hydrophilic surface Effects 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 108010073466 Bombesin Receptors Proteins 0.000 claims 1
- 102000010183 Bradykinin receptor Human genes 0.000 claims 1
- 108050001736 Bradykinin receptor Proteins 0.000 claims 1
- 108050006947 CXC Chemokine Proteins 0.000 claims 1
- 102000019388 CXC chemokine Human genes 0.000 claims 1
- 108091008928 CXC chemokine receptors Proteins 0.000 claims 1
- 102000054900 CXCR Receptors Human genes 0.000 claims 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims 1
- 101800001982 Cholecystokinin Proteins 0.000 claims 1
- 102100025841 Cholecystokinin Human genes 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 102000011652 Formyl peptide receptors Human genes 0.000 claims 1
- 108010076288 Formyl peptide receptors Proteins 0.000 claims 1
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 claims 1
- -1 GPCR-30 Proteins 0.000 claims 1
- 102000011392 Galanin receptor Human genes 0.000 claims 1
- 108050001605 Galanin receptor Proteins 0.000 claims 1
- 102000018899 Glutamate Receptors Human genes 0.000 claims 1
- 108010027915 Glutamate Receptors Proteins 0.000 claims 1
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 claims 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 108010072901 Tachykinin Receptors Proteins 0.000 claims 1
- 102000007124 Tachykinin Receptors Human genes 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 1
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000004671 cell-free system Anatomy 0.000 claims 1
- 229940107137 cholecystokinin Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445740P | 2011-02-23 | 2011-02-23 | |
| US61/445,740 | 2011-02-23 | ||
| PCT/US2012/026353 WO2012116203A1 (en) | 2011-02-23 | 2012-02-23 | Water soluble membrane proteins and methods for the preparation and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508763A JP2014508763A (ja) | 2014-04-10 |
| JP2014508763A5 JP2014508763A5 (enExample) | 2015-04-09 |
| JP6263773B2 true JP6263773B2 (ja) | 2018-01-24 |
Family
ID=46721234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555565A Active JP6263773B2 (ja) | 2011-02-23 | 2012-02-23 | 水溶性膜タンパク質およびその調製および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8637452B2 (enExample) |
| EP (1) | EP2709647B1 (enExample) |
| JP (1) | JP6263773B2 (enExample) |
| KR (1) | KR101963914B1 (enExample) |
| CN (2) | CN108752461A (enExample) |
| AU (3) | AU2012220558A1 (enExample) |
| BR (1) | BR112013020969A2 (enExample) |
| CA (1) | CA2827187C (enExample) |
| CL (1) | CL2013002419A1 (enExample) |
| EA (1) | EA201391041A1 (enExample) |
| IL (2) | IL227886A0 (enExample) |
| MX (1) | MX347038B (enExample) |
| SG (2) | SG192646A1 (enExample) |
| WO (1) | WO2012116203A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2827187C (en) | 2011-02-23 | 2019-01-08 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| EP2968135A4 (en) | 2013-03-14 | 2016-10-26 | Massachusetts Inst Technology | INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES |
| WO2014176524A2 (en) | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
| WO2014176544A1 (en) * | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Water soluble g-protein coupled receptor |
| US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| US20150370960A1 (en) * | 2014-03-27 | 2015-12-24 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| GB2527286A (en) | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
| WO2016025781A1 (en) | 2014-08-15 | 2016-02-18 | Cornell University | Compositions and methods for making water-soluble integral membrane proteins |
| CN104198689A (zh) * | 2014-08-25 | 2014-12-10 | 李洁 | 一种检测g-蛋白耦联受体对缩血管物质反应的方法 |
| CN113929766A (zh) * | 2015-02-18 | 2022-01-14 | 麻省理工学院 | 水溶性跨膜蛋白及其制备和使用方法 |
| CN104946674B (zh) * | 2015-06-17 | 2018-05-01 | 山东大学 | 一种腺苷三磷酸/双磷酸酶及其编码基因与应用 |
| CN106749602A (zh) * | 2016-12-30 | 2017-05-31 | 武汉金开瑞生物工程有限公司 | 一种助表达序列及其在无细胞表达adcy2蛋白中的应用 |
| US11293923B2 (en) | 2017-09-01 | 2022-04-05 | Massachusetts Institute Of Technology | S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof |
| US11414456B2 (en) | 2017-12-11 | 2022-08-16 | Astellas Pharma Inc. | Cell penetrating peptide |
| CN108245686B (zh) * | 2018-01-15 | 2019-08-13 | 中国科学院昆明动物研究所 | 人grk5基因的用途 |
| US11555060B2 (en) * | 2020-03-25 | 2023-01-17 | Avalon GloboCare Corp. | QTY FC fusion water soluble receptor proteins |
| WO2021202186A2 (en) | 2020-03-31 | 2021-10-07 | Massachusetts Institute Of Technology | Qty fc fusion receptor proteins |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US544021A (en) * | 1895-08-06 | William k | ||
| NZ260103A (en) * | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin with alterations in the alpha-helix-1 region |
| US5739273A (en) * | 1992-02-12 | 1998-04-14 | Yale University | Transmembrane polypeptide and methods of use |
| JPH09278793A (ja) * | 1996-04-10 | 1997-10-28 | Kinichiro Miura | ポリペプチド |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| AU768118B2 (en) * | 1999-03-11 | 2003-12-04 | Gryphon Sciences | Chemical synthesis and use of soluble membrane protein receptor domains |
| EP1254227A2 (en) | 2000-02-11 | 2002-11-06 | Amgen Inc. | Fusion receptor from tnf family |
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| CA2517848A1 (en) | 2003-01-21 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa |
| DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
| ATE555126T1 (de) | 2004-08-25 | 2012-05-15 | Janssen Pharmaceutica Nv | Relaxin-chimere polypeptide und deren herstellung und anwendung |
| EP1885746B1 (en) * | 2005-02-08 | 2012-01-11 | Research Development Foundation | Compositions related to soluble g-protein coupled receptors (sgpcrs) |
| BRPI0502759B1 (pt) * | 2005-06-30 | 2014-02-25 | óleo lubrificante e composição lubrificante para uma máquina de refrigeração | |
| WO2007089899A2 (en) * | 2006-02-01 | 2007-08-09 | Oklahoma Medical Research Foundation | Water-soluble (g protein)-coupled receptor protein |
| JO2968B1 (en) | 2006-06-09 | 2016-03-15 | نوفارتيس ايه جي | Polypeptides are a stable insulin-like growth factor |
| CN101688203B (zh) | 2007-03-22 | 2013-12-11 | 赫普泰雅治疗有限公司 | 突变的g蛋白偶联受体及其选择方法 |
| WO2008143910A2 (en) * | 2007-05-18 | 2008-11-27 | University Of Massachusetts | A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| US20110112037A1 (en) | 2008-03-05 | 2011-05-12 | Heptares Therapeutics Limited BioPark | Crystal structure |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| US8809525B2 (en) | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| US20140031525A1 (en) | 2011-01-21 | 2014-01-30 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| CA2827187C (en) | 2011-02-23 | 2019-01-08 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| US20130273585A1 (en) | 2012-04-11 | 2013-10-17 | Gangagen, Inc. | Soluble cytoplasmic expression of heterologous proteins in escherichia coli |
| US20150370960A1 (en) | 2014-03-27 | 2015-12-24 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
-
2012
- 2012-02-23 CA CA2827187A patent/CA2827187C/en not_active Expired - Fee Related
- 2012-02-23 CN CN201810684571.XA patent/CN108752461A/zh active Pending
- 2012-02-23 SG SG2013059811A patent/SG192646A1/en unknown
- 2012-02-23 MX MX2013009715A patent/MX347038B/es active IP Right Grant
- 2012-02-23 US US13/403,725 patent/US8637452B2/en active Active
- 2012-02-23 BR BR112013020969A patent/BR112013020969A2/pt not_active Application Discontinuation
- 2012-02-23 JP JP2013555565A patent/JP6263773B2/ja active Active
- 2012-02-23 EA EA201391041A patent/EA201391041A1/ru unknown
- 2012-02-23 AU AU2012220558A patent/AU2012220558A1/en not_active Abandoned
- 2012-02-23 SG SG10201701547VA patent/SG10201701547VA/en unknown
- 2012-02-23 WO PCT/US2012/026353 patent/WO2012116203A1/en not_active Ceased
- 2012-02-23 CN CN2012800096906A patent/CN103458915A/zh active Pending
- 2012-02-23 KR KR1020137024789A patent/KR101963914B1/ko active Active
- 2012-02-23 EP EP12750085.8A patent/EP2709647B1/en active Active
-
2013
- 2013-08-08 IL IL227886A patent/IL227886A0/en active IP Right Grant
- 2013-08-21 CL CL2013002419A patent/CL2013002419A1/es unknown
- 2013-12-13 US US14/105,252 patent/US9309302B2/en active Active
-
2016
- 2016-03-23 US US15/078,036 patent/US10035837B2/en active Active
- 2016-03-29 AU AU2016201914A patent/AU2016201914A1/en not_active Abandoned
-
2017
- 2017-11-15 AU AU2017261525A patent/AU2017261525A1/en not_active Abandoned
-
2018
- 2018-07-13 US US16/034,549 patent/US20180312562A1/en not_active Abandoned
- 2018-08-14 IL IL261151A patent/IL261151A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101963914B1 (ko) | 2019-03-29 |
| KR20140027117A (ko) | 2014-03-06 |
| US20180312562A1 (en) | 2018-11-01 |
| CN103458915A (zh) | 2013-12-18 |
| EP2709647A1 (en) | 2014-03-26 |
| AU2017261525A1 (en) | 2017-12-07 |
| EP2709647A4 (en) | 2015-01-21 |
| US10035837B2 (en) | 2018-07-31 |
| MX2013009715A (es) | 2014-02-28 |
| MX347038B (es) | 2017-04-10 |
| CA2827187A1 (en) | 2012-08-30 |
| US20120252719A1 (en) | 2012-10-04 |
| US9309302B2 (en) | 2016-04-12 |
| JP2014508763A (ja) | 2014-04-10 |
| IL261151A (en) | 2018-10-31 |
| CL2013002419A1 (es) | 2014-06-06 |
| AU2016201914A1 (en) | 2016-04-21 |
| CA2827187C (en) | 2019-01-08 |
| EA201391041A1 (ru) | 2014-04-30 |
| SG10201701547VA (en) | 2017-03-30 |
| BR112013020969A2 (pt) | 2018-07-10 |
| IL227886A0 (en) | 2013-09-30 |
| AU2012220558A1 (en) | 2013-08-22 |
| SG192646A1 (en) | 2013-09-30 |
| CN108752461A (zh) | 2018-11-06 |
| WO2012116203A1 (en) | 2012-08-30 |
| EP2709647B1 (en) | 2019-08-07 |
| US20140243277A1 (en) | 2014-08-28 |
| US20160264640A1 (en) | 2016-09-15 |
| US8637452B2 (en) | 2014-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6263773B2 (ja) | 水溶性膜タンパク質およびその調製および使用方法 | |
| TWI685501B (zh) | 金屬蛋白酶第三型（ｔｉｍｐ-３）之組織抑制劑之變體、組合物及方法 | |
| JP3868494B2 (ja) | オピオイドアンタゴニストおよびそれらの使用方法 | |
| US8524670B2 (en) | Engineered CXCL12 alpha locked dimer polypeptide | |
| US7863416B2 (en) | Nociceptin-based analgesics | |
| Zachariassen et al. | Probing the molecular interactions between CXC chemokine receptor 4 (CXCR4) and an arginine-based tripeptidomimetic antagonist (KRH-1636) | |
| US20090252705A1 (en) | IL-6/IL-6R Fusion Protein | |
| Ohlstein et al. | Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist | |
| US20180118806A1 (en) | Engineered replacement of partial variant water soluble membrane proteins | |
| US20020064770A1 (en) | Binding compounds and methods for identifying binding compounds | |
| HK1194294B (en) | Water soluble membrane proteins and methods for the preparation and use thereof | |
| HK1194294A (en) | Water soluble membrane proteins and methods for the preparation and use thereof | |
| CN114258317A (zh) | 用于治疗炎性病症的方法和组合物 | |
| US12098175B2 (en) | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof | |
| AU2001247674A1 (en) | Binding compounds and methods for identifying binding compounds | |
| EP1578381A2 (en) | Chemokine antagonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170602 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171031 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171127 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6263773 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |